MML Investors Services
ABCL icon

MML Investors Services’s AbCellera Biologics ABCL Stock Holding History

MML Investors Services’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,509
Closed -$163K – 2150
2022
Q3 		$163K Sell
16,509
-7,700
-32% -$84.5K ﹤0.01% 1971
2022
Q2 		$258K Buy
+24,209
New +$205K ﹤0.01% 1761

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MML Investors Services's ABCL Position: Q4 2022 in Review

MML Investors Services sold out of AbCellera Biologics (ABCL) in Q4 2022, closing a stake of 16,509 shares — an estimated $163K sold.

MML Investors Services first reported a position in ABCL in Q2 2022 and held it in 2 quarters. The position peaked at $258K in Q2 2022. 201 funds tracked by Wall St. Rank hold ABCL as of Q4 2022.

  • MML Investors Services reported no remaining AbCellera Biologics position as of Q4 2022 after selling out during the quarter.
  • MML Investors Services sold 16,509 AbCellera Biologics shares in Q4 2022, an estimated $163K.
  • MML Investors Services first reported a position in AbCellera Biologics in Q2 2022 and held it in 2 quarters.
  • MML Investors Services's AbCellera Biologics position peaked at $258K in Q2 2022.
  • 201 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2022.

Based on MML Investors Services's 13F filing for Q4 2022, filed 13 Feb 2023.